Mineralys Therapeutics will announce Q2 2026 financial results on August 11, 2026, via conference call and webcast.
Quiver AI Summary
Mineralys Therapeutics, Inc. announced that it will release its second-quarter financial results for the period ending June 30, 2026, after market close on August 11, 2026. The results will be discussed in a conference call at 4:30 p.m. ET, and participants can join via domestic and international numbers or through a webcast available on the company's website. Mineralys Therapeutics focuses on developing treatments for hypertension and related conditions, including chronic kidney disease and obstructive sleep apnea, driven by dysregulated aldosterone. Their lead product candidate, lorundrostat, is an investigational oral aldosterone synthase inhibitor. The company is based in Radnor, Pennsylvania, and was founded by Catalys Pacific.
Potential Positives
- Mineralys Therapeutics will report its financial results for Q2 2026 on August 11, indicating transparency and accountability in financial reporting.
- The focus on developing treatments for hypertension and related conditions highlights the company's commitment to addressing significant health issues.
- The company's investigational product candidate, lorundrostat, represents a potentially innovative approach to treatment, which could position Mineralys favorably in the biopharmaceutical market.
Potential Negatives
- The press release does not provide any financial forecasts or insights into performance that investors might expect, potentially raising concerns about transparency.
- The reliance on a single product candidate, lorundrostat, could be seen as a significant risk if the product does not perform as anticipated in clinical trials or market introduction.
- The announcement is focused on an upcoming financial results report and lacks updates on product development timelines or regulatory progress, which could raise questions among stakeholders about the company's operational status.
FAQ
When will Mineralys Therapeutics announce its Q2 2026 financial results?
Mineralys Therapeutics will announce its Q2 2026 financial results on August 11, 2026, after market close.
How can I access the Mineralys Therapeutics Q2 2026 earnings call?
You can access the earnings call by phone at 1-877-704-4453 for domestic callers or 1-201-389-0920 for international callers.
Where can I find the webcast for the conference call?
The live webcast can be found on the “News & Events” page in the Investors section of the Mineralys Therapeutics website.
What is Mineralys Therapeutics' focus?
Mineralys Therapeutics focuses on developing medicines for hypertension and related comorbidities, including chronic kidney disease and obstructive sleep apnea.
What is lorundrostat?
Lorundrostat is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor developed by Mineralys Therapeutics.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MLYS Insider Trading Activity
$MLYS insiders have traded $MLYS stock on the open market 42 times in the past 6 months. Of those trades, 2 have been purchases and 40 have been sales.
Here’s a breakdown of recent trading of $MLYS stock by insiders over the last 6 months:
- CAPITAL MANAGEMENT, L.P. RA has made 2 purchases buying 369,000 shares for an estimated $8,762,797 and 0 sales.
- JON CONGLETON (Chief Executive Officer) has made 0 purchases and 7 sales selling 176,430 shares for an estimated $4,644,543.
- DAVID MALCOM RODMAN (Chief Medical Officer) has made 0 purchases and 29 sales selling 137,957 shares for an estimated $3,733,812.
- ERIC WARREN (Chief Commercial Officer) has made 0 purchases and 2 sales selling 111,562 shares for an estimated $2,896,207.
- DAPHNE KARYDAS has made 0 purchases and 2 sales selling 6,000 shares for an estimated $150,000.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$MLYS Hedge Fund Activity
We have seen 107 institutional investors add shares of $MLYS stock to their portfolio, and 90 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WELLINGTON MANAGEMENT GROUP LLP added 2,574,801 shares (+328.3%) to their portfolio in Q1 2026, for an estimated $69,751,359
- HOLOCENE ADVISORS, LP removed 1,602,035 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $43,399,128
- SAMLYN CAPITAL, LLC removed 1,304,932 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $35,350,607
- CAPITAL INTERNATIONAL INVESTORS removed 1,163,290 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $31,513,526
- ORBIMED ADVISORS LLC added 1,072,500 shares (+109.4%) to their portfolio in Q1 2026, for an estimated $29,054,025
- SPHERA FUNDS MANAGEMENT LTD. added 890,968 shares (+198.4%) to their portfolio in Q1 2026, for an estimated $24,136,323
- JENNISON ASSOCIATES LLC removed 883,427 shares (-69.8%) from their portfolio in Q2 2026, for an estimated $23,834,860
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$MLYS Analyst Ratings
Wall Street analysts have issued reports on $MLYS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- TD Cowen issued a "Buy" rating on 04/27/2026
To track analyst ratings and price targets for $MLYS, check out Quiver Quantitative's $MLYS forecast page.
Full Release
RADNOR, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced it will report its financial results from the second quarter ended June 30, 2026, after the financial markets close on Tuesday, August 11, 2026.
| Tuesday, August 11 th @ 4:30 p.m. ET | |
| Domestic: | 1-877-704-4453 |
| International: | 1-201-389-0920 |
| Conference ID: | 13760792 |
| Webcast: | Link |
A live webcast of the conference call may also be found on the “
News & Events
” page in the Investors section of the Mineralys Therapeutics website.
About Mineralys Therapeutics
Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit
https://mineralystx.com
. Follow Mineralys on
LinkedIn
,
Twitter
and
Bluesky
.
Contact:
Investor Relations
[email protected]
Media Relations
Melyssa Weible
Elixir Health Public Relations
Email:
[email protected]
